A clinical performance study for testing FFPE tissue samples, with therascreen® KRAS RGQ PCR kit, to determine KRAS G12C mutation for potential enrollment into clinical study BO45217 - Performance study: KRAS G12C mutation for enrollment into study BO45217
AN OPEN-LABEL, MULTICENTER, PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY CLINICAL ACTIVITY OF RO7428731 IN PARTICIPANTS WITH GLIOBLASTOMA EXPRESSING MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III - EGFRvIII - BP42573
A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON*S DISEASE - BP43176 IZD334
100 项与 Roche Nederland BV 相关的临床结果
0 项与 Roche Nederland BV 相关的专利(医药)
100 项与 Roche Nederland BV 相关的药物交易
100 项与 Roche Nederland BV 相关的转化医学